Castle Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Castle Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 154.3 times by its yearly operating cash. Higher than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.6×Over the last 3 years its own operating cash covered its investment spending (capex) 1.6 times.
Higher than 71% of Healthcare companies in United States.
Cash Locked Ratio
$10For every $100 of sales, $10 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $17 tied up three years earlier.
Less money tied up than 80% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$21Sales grew 151% in 3 years; of every extra $100 of sales, $21 became extra profit.
Higher than 52% of Healthcare companies in United States.
Asset Productivity Ratio
+151% / +29%In 3 years sales changed by +151% while total assets changed by +29%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
154.3×Debt due within a year is covered 154.3 times by its yearly operating cash.
Higher than 98% of Healthcare companies in United States.
Cash Cushion Ratio
+26%Cash, after subtracting all debt, equals 26% of its market value (net cash).
Higher than 67% of Healthcare companies in United States.
Tangible Assets Ratio
83%Of every $100 the company owns, $83 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 53% of Healthcare companies in United States.
Tangible Net Worth Ratio
79%Of every $100 of net worth, $79 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 61% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Castle Biosciences, Inc. made a loss over the last year. Castle Biosciences, Inc. owes $0.16 for every $1 it owns. Castle Biosciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCastle Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.16The share price is 2.16 times Castle Biosciences, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$1.0 BThe total market value of all of Castle Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$470 MWhat Castle Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$15.39Net worth divided by the number of shares. The share price of $33.19 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-4.2%Castle Biosciences, Inc. lost 4.2% of its shareholders' money over the last year, higher than 74% of Healthcare companies in United States.
Owes vs Owns
0.16×Castle Biosciences, Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Dividend yield
NoneCastle Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 36% a year on average over 3 years.
Profit growth
LossCastle Biosciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-7.0%Castle Biosciences, Inc. lost $7 for every $100 of revenue.
Interest cover
Not coveredCastle Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCastle Biosciences, Inc. held $263 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Castle Biosciences, Inc.: $1.0 B ÷ $470 M (30 Jun 2026) = 2.2.
What is Castle Biosciences, Inc.'s return on equity?
Castle Biosciences, Inc. lost 4.2% of its shareholders' money over the last year, higher than 74% of Healthcare companies in United States.
How much does Castle Biosciences, Inc. owe compared with what it owns?
Castle Biosciences, Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Does Castle Biosciences, Inc. pay a dividend?
No. Castle Biosciences, Inc. does not currently pay a dividend.
Is Castle Biosciences, Inc.'s revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 36% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.